Logo

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Share this
Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Tuba Khan

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Shots:

  • The P-I/II KRYSTAL–1 study evaluates adagrasib (600mg- bid) as monothx. and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation following prior systemic therapy
  • The therapy showed the clinical activity and broad disease control. As of May 25 & July 9- 2021- 80% of patients received adagrasib mononthx. & 90% with combination; median follow up of 8.9 & 7mos.; response rate (22% & 43%) including unconfirmed PR (1 & 2); DCR (87% & 100%) respectively- m-DoR (4.2mos.) & m-PFS (5.6mos.) in monothx. therapy
  • Additionally- the therapy was well-tolerated with a manageable safety profile- grade 3/4 TRAEs (30% in monothx. & 16% in combination)

Click here to­ read full press release/ article | Ref: Mirati | Image: Trading View

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

You May Also Like

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family